Related Experiment Video
Updated: Aug 1, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
Modified Glasgow Prognostic Score as a Marker for Predicting Outcomes in Patients with either Bladder or Prostate
Jie Chen1, Suna Fu1, Jianhong Yu1
1Department of Geriatrics, Affiliated Hospital of Shaoxing University, Shaoxing, China.
Introduction:
The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).
Methods:
A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).
Results:
Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p > 0.05). These associations remained valid in subgroup analysis.
Conclusion:
Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.
